Constantine S. Tam, MD
The combination of venetoclax (Venclexta) and ibrutinib (Imbruvica) induced a 16-week complete response (CR) rate of 42% per CT imaging in patients with previously untreated or relapsed/refractory mantle cell lymphoma (MCL).
Fourteen (58%) patients experienced serious AEs. Six patients died during the study, 4 of which were due to disease progression. Of the other 2 deaths, 1 patient died from malignant otitis externa during week 6 after treatment with ibrutinib alone and the other died from cardiac failure during ongoing complete response.
Tam CS, Anderson MA, Pott C, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma [published online March 29, 2018]. N Engl J Med. 2018; 378:1211-23. doi: 10.1056/NEJMoa1715519.
... to read the full story